Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20087874 | 0.96 | CALM1 (0.41) | TP53KDM4EL3MBTL1LTB4RCALM1 | |
| SCHEMBL20087912 | 0.88 | CYP11B1 (0.38) | KDM4EL3MBTL1CALM1 | |
| SCHEMBL20087910 | 0.87 | BRD4 (0.42) | TP53KDM4EL3MBTL1 | |
| SCHEMBL20087909 | 0.85 | TGFBR1 (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL20087908 | 0.84 | KDM4E (0.39) | KDM4EL3MBTL1HRH4 | |
| SCHEMBL20087875 | 0.84 | LTA4H (0.38) | TP53EGLN1 | |
| SCHEMBL20087872 | 0.82 | LTA4H (0.37) | TP53KDM4E | |
| SCHEMBL20087911 | 0.82 | ROCK1 (0.37) | KDM4EL3MBTL1CALM1 | |
| SCHEMBL20087906 | 0.82 | HPGD (0.49) | L3MBTL1HRH4 | |
| SCHEMBL14665699 | 0.80 | NPSR1 (0.40) | TP53LTB4RCALM1HTR2CADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | TP53 292/4885KDM4E 1568/4885L3MBTL1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.